Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on October 13, 2010, to report a material definitive agreement. Specifically, the company entered into an underwriting agreement with Citigroup Global Markets Inc. on October 7, 2010, for the sale of approximately 6.3 million shares of its common stock. The shares were offered at a price of $27.69 per share. This filing is significant for investors as it details a capital raise event, which can impact share dilution and provide the company with additional funds for research, development, and operations. The offering price suggests a specific valuation at that time, and the details of the underwriting agreement are crucial for understanding the terms of the share sale.
Key Highlights
- 1Regeneron Pharmaceuticals entered into an underwriting agreement on October 7, 2010.
- 2The agreement is with Citigroup Global Markets Inc.
- 3The company will sell 6,325,000 shares of its common stock.
- 4The offering price for the shares is $27.69 per share.
- 5This is a material definitive agreement, indicating a significant corporate action.
- 6The filing serves to publicly disclose the terms of this capital raise.